Nuvation Bio (NYSE:NUVB) Earns “Buy” Rating from HC Wainwright

Nuvation Bio (NYSE:NUVB – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $21.00 target price on the stock. HC Wainwright‘s target price indicates a potential upside of 454.82% from the stock’s current price.

Other equities analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. Citizens Jmp reiterated a “market outperform” rating and set a $10.00 price target on shares of Nuvation Bio in a research report on Wednesday, September 16th. Wall Street Zen cut shares of Nuvation Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. JPMorgan Chase & Co. began coverage on shares of Nuvation Bio in a research note on Tuesday, August 18th. They set an “overweight” rating and a $13.00 price target on the stock. Finally, Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research report on Monday, October 19th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nuvation Bio has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Check Out Our Latest Research Report on Nuvation Bio

Nuvation Bio Price Performance

Shares of NYSE:NUVB opened at $3.79 on Tuesday. The company’s fifty day moving average price is $4.96 and its 200-day moving average price is $5.31. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -9.46 and a beta of 1.73. Nuvation Bio has a one year low of $3.77 and a one year high of $9.75. The company has a debt-to-equity ratio of 1.23, a current ratio of 7.45 and a quick ratio of 7.30.

Nuvation Bio (NYSE:NUVB – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The company had revenue of $44.95 million during the quarter, compared to the consensus estimate of $34.39 million. Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%. On average, equities research analysts anticipate that Nuvation Bio will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nuvation Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its holdings in shares of Nuvation Bio by 847.9% in the 3rd quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock valued at $47,000 after acquiring an additional 7,504 shares during the last quarter. KBC Group NV purchased a new position in shares of Nuvation Bio during the first quarter worth $37,000. GK Wealth Management LLC purchased a new position in shares of Nuvation Bio during the third quarter worth $52,000. Emergent Wealth Advisors LLC purchased a new position in shares of Nuvation Bio during the third quarter worth $67,000. Finally, Tortoise Investment Management LLC acquired a new position in Nuvation Bio during the second quarter valued at $78,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

See Also

Analyst Recommendations for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.